SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hiromitsu Kumada, Ken Sato, Tetsuo Takehara, Makoto Nakamuta, Masatoshi Ishigami, Kazuaki Chayama, Joji Toyota, Fumitaka Suzuki, Yoshiyuki Nakayasu, Miyoko Ochi, Ichimaro Yamada, Takeshi Okanoue, Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan, Hepatology Research, 2015, 45, 6
  2. 2
    Liang-Tzung Lin, Chueh-Yao Chung, Wen-Chan Hsu, Shun-Pang Chang, Ting-Chun Hung, Justin Shields, Rodney S. Russell, Chih-Chan Lin, Chien-Feng Li, Ming-Hong Yen, D. Lorne J. Tyrrell, Chun-Ching Lin, Christopher D. Richardson, Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry, Journal of Hepatology, 2015, 62, 3, 541

    CrossRef

  3. 3
    Santseharay Ramirez, Yi-Ping Li, Sanne B. Jensen, Jannie Pedersen, Judith M. Gottwein, Jens Bukh, Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors, Hepatology, 2014, 59, 2
  4. 4
    Lai Wei, Anna S.F. Lok, Impact of New Hepatitis C Treatments in Different Regions of the World, Gastroenterology, 2014, 146, 5, 1145

    CrossRef

  5. 5
    Stefan Zeuzem, Geoffrey M. Dusheiko, Riina Salupere, Alessandra Mangia, Robert Flisiak, Robert H. Hyland, Ari Illeperuma, Evguenia Svarovskaia, Diana M. Brainard, William T. Symonds, G. Mani Subramanian, John G. McHutchison, Ola Weiland, Hendrik W. Reesink, Peter Ferenci, Christophe Hézode, Rafael Esteban, Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3, New England Journal of Medicine, 2014, 370, 21, 1993

    CrossRef

  6. You have free access to this content6
    Marc Bourlière, Astrid Wendt, Hélène Fontaine, Christophe Hézode, Stanislas Pol, Jean Pierre Bronowicki, How to optimize HCV therapy in genotype 1 patients with cirrhosis, Liver International, 2013, 33,
  7. 7
    THT Nguyen, J Guedj, J Yu, M Levi, F Mentré, Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome, CPT: Pharmacometrics & Systems Pharmacology, 2013, 2, 7
  8. 8
    E. B. Tapper, N. H. Afdhal, Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3, Journal of Viral Hepatitis, 2013, 20, 10
  9. 9
    Silvia Alboni, Lara Gibellini, Claudia Montanari, Cristina Benatti, Stefania Benatti, Fabio Tascedda, Nicoletta Brunello, Andrea Cossarizza, Carmine M. Pariante, N-acetyl-cysteine prevents toxic oxidative effects induced by IFN-α in human neurons, The International Journal of Neuropsychopharmacology, 2013, 16, 08, 1849

    CrossRef

  10. 10
    Alessio Aghemo, Raffaele De Francesco, New horizons in hepatitis C antiviral therapy with direct-acting antivirals, Hepatology, 2013, 58, 1
  11. 11
    Noémie Calland, Jean Dubuisson, Yves Rouillé, Karin Séron, Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?, Viruses, 2012, 4, 12, 2197

    CrossRef

  12. 12
    Ezequiel Ridruejo, Predictors of response to chronic hepatitis C treatment, Future Virology, 2012, 7, 11, 1089

    CrossRef